RT @richtrades100: @BertrandBio @A_May_MD A silver lining, possibly appearing. Many biotechs beyond ATLs, could be an opportunity. Worth no…

RT @Sports_bios: I'll say this again - esp. in light of multiple news events today - TOO DARN BAD that $BIIB does not have the capacity - a…

RT @CrocsAnalyst: $VYGR ouch

RT @EugeneNg_VCap: You cannot pick your return, you can only pick the risk. You have to decide how much risk you are willing to take. It i…

RT @Quantumup1: H.C. Wainwright reiterated $VKTX Buy-$102. $LLY $NVO $GPCR $TERN "Yesterday after the close, Viking announced 4Q24 and 202…

RT @bioinvestor24: $VKTX $PFE $NVO $LLy Viking. Raymond James increased prices target $125. Strong buy

RT @doepke_michel: $LLY vs. $NVO. #Obesity

Although Vivek R. might have nothing to do anymore at all, $IMVT remains his progeny. I don't know if his bad luck still stays attached with the company. I'll just amuse myself from the sidelines.

RT @TomSilver39: JPM:" $VKTX 4Q24 Review: No Major Updates - Ph3 SubQ On Track To Start In 2Q25..."

@Biohazard3737 @Biotech_DD I think obesity is large enough of a market with strong enough of a demand, now and in future that late comers should also be able to gain substantial share of the market. And it's not like they are giving up altogether $VKTX.

@adamfeuerstein @AaronRosenblum5 @avidresearch Adam said it. Just by the virtue of being a publicly traded company they have a fundamental duty to shareholders and share price, both long and or short term. Anyways, I do hope that the data is genuinely surprise on the good side. Playing small long. $KURA

@AaronRosenblum5 ASCO late breaker presentation in itself would kinda suggest good data though, doesn't it?

@adar170 @MSollender @bigpharmaguy I really don't understand WHY do they do this? Do they think no one is going to question? No one wants to see actual data that they claim positive? Putting (stunt) PR like this promotes their reputation? This only leads to more scrutiny $KURA

Got some $NVO. Wish I could've bought more. Already have a full position of $VKTX. Not gonna be like Vas Narasimhan $NVS 😉

@Biohazard3737 I think a smart person should buy something that has more chance of success like $VKTX and also buy something else. Nobody is stopping them from buying two assets... except their own stupidity.

RT @andrewpannu: PD-L1 x VEGF landscape analysis Besides Merck, no pharma with an approved PD-(L)1 inhibitor has made a move yet, but the…

@aayushtrades Just an FYI

RT @Barchart: "Earnings don't matter when Trump is your friend" - Incredible headline for Tesla $TSLA 🫡

@aayushtrades $TSLA is mostly hot air. Elon keeps talking big s hit. That's what most of the"valuation" is propped on.